GC
AXSM icon

Guggenheim Capital’s Axsome Therapeutics AXSM Stock Holding History

Guggenheim Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.75M Buy
16,250
+3,220
+25% +$556K 0.02% 608
2025
Q4 		$2.38M Buy
13,030
+513
+4% +$71.6K 0.02% 625
2025
Q3 		$1.52M Buy
12,517
+3,065
+32% +$345K 0.01% 779
2025
Q2 		$987K Sell
9,452
-751
-7% -$79.5K 0.01% 890
2025
Q1 		$1.19M Sell
10,203
-1,403
-12% -$160K 0.01% 819
2024
Q4 		$982K Sell
11,606
-1,766
-13% -$162K 0.01% 932
2024
Q3 		$1.2M Sell
13,372
-1,615
-11% -$141K 0.01% 1012
2024
Q2 		$1.21M Sell
14,987
-2,255
-13% -$167K 0.01% 1024
2024
Q1 		$1.38M Buy
17,242
+2,362
+16% +$198K 0.01% 1046
2023
Q4 		$1.18M Buy
+14,880
New +$995K 0.01% 1068

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Guggenheim Capital's AXSM Position: Q1 2026 in Review

Guggenheim Capital increased its Axsome Therapeutics (AXSM) stake by 25% in Q1 2026, buying an estimated $556K and bringing the position to 16,250 shares worth $2.75M. The position accounts for 0.02% of the portfolio, ranked #608.

Guggenheim Capital first reported a position in AXSM in Q4 2023 and has held it in 10 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Guggenheim Capital held 16,250 shares of Axsome Therapeutics worth $2.75M as of Q1 2026.
  • Guggenheim Capital bought 3,220 Axsome Therapeutics shares in Q1 2026, an estimated $556K.
  • Axsome Therapeutics made up 0.02% of Guggenheim Capital's portfolio in Q1 2026, its #608 holding.
  • Guggenheim Capital first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.